全反式维甲酸在实体瘤中临床应用进展  

Progress in the clinical application of all-trans-retinoic acid in solid tumors

作　　者：阮聪 钱佳佳 杜琼 翟青[1,2,3] 孙晓敏 徐蕊[1] RUAN Cong;QIAN Jiajia;DU Qiong;ZHAI Qing;SUN Xiaomin;XU Rui(Department of Pharmacy,Fudan University Shanghai Cancer Center Minhang Branch,Shanghai 200240,China;Department of Pharmacy,Fudan University Shanghai Cancer Center,Shanghai 200032,China;Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China;Shandong LONGFINE Pharmaceutical Co.,Ltd.,Jining 272600,Shandong Province China)

机构地区：[1]复旦大学附属肿瘤医院闵行分院药剂科,上海200240 [2]复旦大学附属肿瘤医院药剂科,上海200032 [3]复旦大学上海医学院肿瘤学系,上海200032 [4]山东良福制药有限公司,山东济宁272600

出　　处：《世界临床药物》2024年第7期697-702,共6页World Clinical Drug

基　　金：上海市闵行区卫生健康系统优秀青年药学人才计划(MWYJYX03);上海市闵行区自然科学研究课题(2022MHZ040)。

摘　　要：全反式维甲酸(all-trans-retinoic acid,ATRA)是治疗急性早幼粒细胞白血病(acute promyelocytic leukemia)的临床首选药物。然而近年来大量研究表明,ATRA可通过抑制肿瘤干细胞的免疫逃逸效应以及促进髓源性抑制细胞的分化等机制来维持人体正常免疫微环境,进而增强化疗、靶向和免疫治疗药物在实体瘤中的疗效。该文就ATRA在实体瘤中的临床研究进展作一综述,为其进一步临床应用提供参考。All-trans-retinoic acid(ATRA)is the clinical choice for the treatment of acute promyelocytic leukemia.However,in recent years,a large number of studies have shown that ATRA maintains the human normal immune microenvironment by inhibiting the immune escape effect of tumor stem cells and promoting the differentiation of myeloid-derived suppressor cells,and enhances the efficacy of chemotherapeutic drugs,targeted drugs and immunotherapy drugs in solid tumors.This paper reviewed the clinical trial progress of ATRA in solid tumors to provide a reference for its further clinical application.

关 键 词：全反式维甲酸 实体瘤 肿瘤干细胞 髓源性抑制细胞 免疫调节 

分 类 号：R733.71[医药卫生—肿瘤]